STG Acquires ImpactRx
Merck Capital Ventures (MCV), the venture capital arm of Merck and one of ImpactRx’s existing investors, will maintain its investment in ImpactRx. Under the terms of the acquisition
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.